Recruiting

Dupilumab

Sponsor:

UCLA

Code:

NCT05858619

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dupilumab

Study Details

Brief summary:

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Conditions

Atopic Dermatitis

Study ID

NCT05858619

Start date

Feb 1, 2023

Status verified date

Jun, 2026

Completion date

Feb 1, 2028

Anticipated

Primary completion date

Feb 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. 18 years of age or older
2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7

Exclusion Criteria:

1. Known pregnancy
2. Known immunodeficiencies
3. Known parasitic infection -

Study Design

Enrollment

15 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: dupilumab treatment

Treatment with IL4RA inhibitor

Interventions

Dupilumab

dupilumab 600 mg injection initially and then 300 mg every other week

Primary outcome measure

  • Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks [ Time Frame: baseline and 8-12 weeks ]

Central Contacts and Locations

Central contacts

Jeffrey Cheng, MD, PhD

415 575 0524rashes@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Jeffrey Cheng, MD, PhD

rashes@ucsf.edu

More Information

Sponsor

University of California, San Francisco

Last update posted

Jun 4, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-06-04.